From Neurons to Drones: MSX's Pre-IPO Bet on Neuralink and Anduril Exposes the Real AI Frontier

In the ashes of Terra, we didn't just learn about algorithmic stablecoins; we learned about the fragility of narratives built on thin air. Today, a different kind of narrative is being constructed, one that moves from the abstract digital realm into the physical and biological worlds. The news that MSX's Pre-IPO Phase 3 fund has brought Neuralink and Anduril into its portfolio is not just another venture capital headline. It is a signal, a stark admission from the smart money that the next phase of the AI gold rush isn't about chatbots or image generators. It's about owning the interface to the human mind and the operating system for the modern battlefield. This isn't a diversification play; it's a bet on the two most extreme, and potentially most lucrative, endpoints of AI's expansion. As someone who has spent years dissecting smart contracts and protocol mechanics, I find this move less about the companies themselves and more about the map MSX is drawing for the future of value creation. Let's pull back the curtain on this deal, because the technical realities and the unspoken risks are far more interesting than the press release suggests. To understand why this pairing is so significant, we have to strip away the hype and look at the fundamental state of play for both companies. Neuralink, founded by Elon Musk, is operating in the realm of invasive brain-computer interfaces (BCI). Their N1 chip, with its 1,024 channels, is a marvel of engineering, but it is also a product still in its infancy. As of late 2025, they have performed just three human implants. They received FDA breakthrough device designation, and in November 2025, they got the green light for the 'CONVOY' feasibility study, which aims to connect the N1 chip to a robotic arm, allowing paralyzed patients to control it with their thoughts. This is profound, life-altering technology, but it is a far cry from a commercial product. On the other hand, Anduril is a defense technology company that has already crossed the chasm. Their Lattice software platform, which uses AI for sensor fusion and autonomous decision-making, is not a prototype; it is deployed. With an estimated $1 billion in revenue for 2025, a 150% year-over-year increase, and a recent $1.3-1.4 billion acquisition of UK-based 3D printing drone company Callum, Anduril is scaling. They are the poster child for 'software-defined defense,' moving from the digital world of algorithms to the physical world of drones, submarines, and missile warning systems. The contrast is stark: one company is proving the science, the other is scaling the business. MSX is betting on both, which tells me they are looking at a timeline that extends well beyond the next earnings report. The core of this analysis, however, lies in the technical and commercial trajectories that are often glossed over in the mainstream press. For Neuralink, the path to commercialization is a gauntlet of regulatory and biological hurdles. They are currently in the FDA's Investigational Device Exemption (IDE) phase, which is strictly for research. The timeline for a De Novo or PMA approval is likely 2026-2027, but this is contingent on long-term safety data that simply doesn't exist yet. We are talking about electrode degradation, signal attenuation over time, and the body's immune response to a foreign object in the brain. These are not trivial engineering problems; they are biological unknowns. Based on my experience auditing complex systems, the risk here is not whether the tech works in a demo, but whether it works reliably in the messy, chaotic environment of a human body for years on end. The valuation, estimated between $8-10 billion in a recent round, is pricing in a future that is far from guaranteed. Anduril, by contrast, has a clearer, though not easier, path. Their revenue is real, but their valuation, potentially between $25-30 billion, is based on a P/S ratio of 14-28x. This is lower than Palantir's 30-50x, but it assumes a continued flood of government contracts. The recent $250 million 'Large Scale Expeditionary Warfare' contract from the DIU is a good sign, but it also highlights a dangerous concentration risk. Anduril's fate is tied to the whims of the US Department of Defense and the broader geopolitical climate. A shift in budget priorities or a de-escalation in global tensions could put a serious dent in their growth story. The investment thesis for MSX is clear: get in before the IPO, ride the narrative, and exit with a 3-5x return. But the execution risk is immense. Now, let's talk about the contrarian angle, the part of this story that no one in the echo chamber wants to address. The narrative being sold is one of 'AI for the betterment of humanity' and 'AI for national security.' But what if we look at this as a single, unified bet on the commodification of human cognition and the automation of violence? The 'from human brain to battlefield' tagline is catchy, but it obscures a more uncomfortable truth. By investing in both, MSX is essentially hedging against two possible futures: one where AI augments human capability from the inside, and one where AI replaces human decision-making on the outside. This is not a contradiction; it's a portfolio strategy for the end of the 'human-in-the-loop' era. The unspoken risk here is not technical failure, but ethical and societal backlash. Neuralink's invasive approach is already facing scrutiny over animal welfare and the very concept of cognitive enhancement. Anduril's autonomous weapons systems are at the center of a global debate on lethal autonomous weapons (LAWS). A single high-profile malfunction, a 'rogue drone' incident, or a severe adverse event in a Neuralink patient could trigger a regulatory and public relations firestorm that would decimate valuations. The market is currently pricing in a smooth, linear progression from where we are to a sci-fi future. But history, especially in the crypto and tech worlds, has shown us that progress is rarely linear. It's a series of booms, busts, and brutal corrections. The 'liquidity fragmentation' narrative we see in DeFi is a manufactured problem to sell new products; similarly, the 'AI frontier' narrative here might be a manufactured vision to justify astronomical valuations for companies with, in one case, zero revenue. This brings me to the core of what I believe is the real story. The introduction of Neuralink and Anduril into a Pre-IPO fund is a masterclass in narrative construction, but it is also a high-stakes gamble on the pace of technological maturity. The 'AI+Hard Tech' label is a magnet for capital, but it often masks a fundamental mismatch between expectations and reality. Neuralink's valuation is a pure options play on a future that may be a decade away. Anduril's valuation is a growth play that is entirely dependent on a single, albeit massive, customer. The 'information gain' here is not that MSX made this investment, but that they are willing to accept the extreme tail risks associated with both companies. They are betting that the 'AI arms race' and the 'human enhancement race' will accelerate, not stall. In the ashes of the last bull market, we learned that narratives without fundamentals collapse. The question now is whether the fundamentals of brain-computer interfaces and autonomous defense can catch up to the narrative before the market's patience runs out. The next 24 months will be critical. We will see if Neuralink can expand its patient cohort and produce compelling long-term safety data. We will see if Anduril can diversify its revenue base beyond the Pentagon and prove its hardware can scale. The smart money is in, but the real test is just beginning. Are we witnessing the birth of a new industrial era, or are we just watching the next bubble inflate? The answer, as always, lies in the code, the data, and the unglamorous, unrelenting march of technical progress. And that is a story worth watching closely.